Last edition
News about "Sun Pharma "
Sun Pharma Introduces ILUMYA in India for Plaque Psoriasis Treatment
Sun Pharma has launched its global innovative drug, ILUMYA (Tildrakizumab), in India for the treatment of moderate-to-severe plaque psoriasis.
Sun Pharma | 01/12/2025 | By Dineshwori
US FDA Approves Label Update for Sun Pharma's UNLOXCYT
Sun Pharma has received US FDA approval for a label update to UNLOXCYT, the first and only PD-L1 inhibitor for advanced Cutaneous Squamous Cell Carcinoma (aCSCC), further supporting its clinical value with durable responses and a favourable safety profile for patients with multiple comorbidities.
Sun Pharma | 27/11/2025 | By Dineshwori
AstraZeneca and Sun Pharma have entered into a second exclusive brand partnership to expand access to Sodium Zirconium Cyclosilicate (SZC) in India for the management of Hyperkalaemia.
Sun Pharma | 17/11/2025 | By Dineshwori | 381
Sun Pharma Presents Two Posters on Utreglutide at ObesityWeek 2025
Sun Pharma presented new clinical data on its investigational GLP-1 agonist, Utreglutide, at ObesityWeek 2025, highlighting meaningful reductions in body weight, waist circumference, and lipid parameters across two studies, with the therapy showing a favourable and class-consistent safety profile.
Sun Pharma | 14/11/2025 | By Dineshwori | 141
Trump's 100 Percent Pharma Tariff to Have Twofold Impact on Indian Drugmakers
The proposed tariffs target only branded and patented medicines, leaving India’s generic exports largely unaffected. While companies making branded drugs for the US may face challenges, domestic generic producers could benefit from increased demand for affordable alternatives.
Sun Pharma | 29/09/2025 | By Dineshwori | 421
Emcure Pharma Taps Industry Veteran R.S. Vasan to Lead India Business
Emcure Pharmaceuticals Ltd. has appointed R.S. Vasan as President – India Business and Senior Management Personnel (SMP).
Sun Pharma | 16/07/2025 | By Dineshwori | 297
Sun Pharma to Acquire Checkpoint Therapeutics
Checkpoint has received approval from the US Food & Drug Administration (FDA) for UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation.
Sun Pharma | 10/03/2025 | By Aishwarya | 165
Sun Pharma Presents New Clinical Efficacy and Safety Data in Dermatology at EADV Congress
The company will also share results in two additional posters for deuruxolitinib, which showed clinically meaningful improvement in anxiety and depression among patients taking deuruxolitinib to treat their severe AA (P2022) as well as dose optimization for deuruxolitinib at 8 mg (P2081).
Sun Pharma | 27/09/2024 | By Aishwarya | 800
Sun Pharma and Moebius Medical Receive FTD for MM-II for Treatment of Osteoarthritis Knee Pain
Sun Pharma and Moebius Medical have announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to MM-II (Large Liposomes of DPPC and DMPC) for the treatment of osteoarthritis knee pain.
Sun Pharma | 07/09/2024 | By Aishwarya | 271
Sun Pharma Signs Non-Exclusive Patent Licensing Deal with Takeda for Vonoprazan
Sun Pharma has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Ltd. to commercialise Vonoprazan tablets 10 mg, 20 mg in India under the brand name Voltapraz.
Sun Pharma | 24/06/2024 | By Aishwarya | 949
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy